A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

The sponsors of this investigational drug are developing prasugrel as a possible treatment for patients with acute coronary syndrome (heart attack or chest pain) who need, or are expected to need, a percutaneous coronary intervention (PCI; also called a balloon angioplasty). Prasugrel will be compared with clopidogrel to determine which drug is better at reducing deaths, future heart attacks, or stroke.

Official Title

A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

Conditions

Coronary Arteriosclerosis

Study Type

Interventional

Study Design

Treatment

Further Details

Study Start

Eligibility & Criteria

Inclusion Criteria:- A person who has been diagnosed with acute coronary syndrome and is to undergo a percutaneous intervention. – A person who is of the legal age of 18 and is mentally competent to provide a signed written informed consent. – If a woman is of childbearing potential (i.e., before menopause), she must test negative for pregnancy and agree to use a reliable method of birth control. Exclusion Criteria:-A person who has had a stroke within the last 3 months. – A person who has active internal bleeding or has a history of a bleeding disorder. – Individuals who are at an increased risk of bleeding based on laboratory criteria evaluated by the treatment physician. – A person who has liver disease; for example, cirrhosis. – A person who has a condition such as alcoholism, mental illness, or is drug dependent.

Total Enrolment

Contact Details

Clinical Trials Support Center at (1-877-285-4559), Global Quintiles Study Line (1-866-615-4672) or speak with your personal physician. Australian studies conducted in NSW, SA, Victoria and Queensland.